Recurrence of hepatitis C virus (genotype 4) infection after living-donor liver transplant in Egyptian patients

Experimental and Clinical Transplantation

Volumn 7, Issue 3, 2009, Pages 157-163

  Yosry, Ayman ^a,b   Abdel Rahman, Mahasen ^a,b   Esmat, Gamal ^a,b   El Serafy, Magdy ^a,b   Omar, Ashraf ^a,b   Doss, Waheed ^a,b   Zayed, Nagla ^a,b   Said, Mohamed ^a,b   Ismail, Tamer ^a,b   Hosny, Adel ^a,b   Marawan, Ebrahem ^a,c   El Malt, Osama ^a,g   Kamel, Refaat Refaat ^a,d   Hatata, Yaser ^a,b   El Taweel, Ahmad ^a,e   Ghali, Ahmad ^a,e   Sabri, Hussein ^a,e   Kamel, Sanaa ^a,f   El Gabaly, Hatem ^a,f  

^a Dar Al Fouad Hospital   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c MENOUFIA UNIVERSITY   (Egypt)

^d AIN SHAMS UNIVERSITY   (Egypt)

^e AIN SHAMS UNIVERSITY   (Egypt)

^f CAIRO UNIVERSITY   (Egypt)

^g NATIONAL CANCER INSTITUTE   (Egypt)

Author keywords

Hepatitis C recurrence; Liver transplant; Outcome post LDLT

Indexed keywords

AMINOTRANSFERASE; CYCLOSPORIN; HEPATITIS B CORE ANTIGEN; INTERFERON; STEROID; TACROLIMUS;

ADULT; ARTICLE; DEMOGRAPHY; DRUG PULSE THERAPY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EGYPT; FEMALE; FOLLOW UP; GENOTYPE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; OUTCOME ASSESSMENT; PATIENT MONITORING; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; RECURRENT INFECTION; SCORING SYSTEM; STEROID THERAPY; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS REPLICATION;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; BIOPSY; CARCINOMA, HEPATOCELLULAR; EGYPT; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; RNA, VIRAL; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 75149198826     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Brown RS. Hepatitis C and liver transplantation. Nature. 2005;436(7053):973-978.
2. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122(4):889-896.
3. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol. 2000;32(4):673-684.
4. Shiffman ML, Stravitz RT, Contos MJ, et al. Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl. 2004;10(10):1248-1255.
5. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124(1):91-96.
6. Féray C, Gigou M, Samuel D, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology. 1995;108(4):1088-1096.
7. Prieto M, Berenguer M, Rayón JM, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology. 1999;29(1):250-256.
8. Berenguer M. Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transpl. 2003;9(11):S44-S47.
9. El-Meteini M, Fayez A, Fathy M, et al. Living related liver transplantation in Egypt: an emerging program. Transplant Proc. 2003;35(7):2783-2786.
10. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med. 1996;334(13):815-820.
11. Garcia-Retortillo M, Forns X, Llovet JM, et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology. 2004;40(3):699-707.
12. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology. 2002;36(1):202-210. Erratum in: Hepatology. 2003;37(2):489.
13. Berenguer M, Prieto M, Córdoba J, et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol. 1998;28(5):756-763.
14. Onaca NN, Levy MF, Netto GJ, et al. Pretransplant MELD score as a predictor of outcome after liver transplantation for chronic hepatitis C. Am J Transplant. 2003;3(5):626-630.
15. Cameron AM, Ghobrial RM, Hiatt JR, et al. Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Ann Surg. 2006;244(4):563-571.
16. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999;341(1):22-26.
17. Charlton M. Hepatitis C infection in liver transplantation. Am J Transplant. 2001;1(3):197-203.
18. Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl. 2006;12(8):1192-1204.
19. Gretch D, Wile M, Gaur L. Donor-recipient match at the HLADQB locus is associated with recrudescence of chronic hepatitis following liver transplantation for end stage hepatitis C. NEJM. Volume 1996: Number 13, 334:815-821
20. Charlton M. Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence. Liver Transpl. 2003;9(11):S58-S62.
21. Gane EJ, Naoumov NV, Qian KP, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology. 1996;110(1):167-177.
22. Papatheodoridis GV, Barton SG, Andrew D, et al. Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimens. Gut. 1999;45(3):427-434.
23. Yosry A, Esmat G, El-Serafy M, et al. Outcome of living donor liver transplantation for Egyptian patients with hepatitis C (genotype 4)-related cirrhosis. Transplant Proc. 2008;40(5):1481-1484.
24. Herrero JI, de la Peña A, Quiroga J, et al. Risk factors for recurrence of hepatitis C after liver transplantation. Liver Transpl Surg. 1998;4(4):265-270.
25. Oton E, Barcena R, Castillo M, et al. Hepatitis C virus recurrence after liver transplantation: influence of immunosuppressive regimens on viral load and liver histology. Transplant Proc. 2006;38(8):2499-2501.
26. Berenguer M, Palau A, Fernandez A, et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl. 2006;12(7):1067-1076.
27. Hilgard P, Kahraman A, Lehmann N, et al. Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation: effects on virus replication and recurrent hepatitis. World J Gastroenterol. 2006;12(5):697-702.
28. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl. 2003;9(11): S28-S34.
29. Russo MW, Galanko J, Beavers K, Fried MW, Shrestha R. Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl. 2004;10(3):340-346.
30. Takada Y, Haga H, Ito T, et al. Clinical outcomes of living donor liver transplantation for hepatitis C virus (HCV)-positive patients. Transplantation. 2006;81(3):350-354.